Zinzani P L, Barbieri E, Gherlinzoni F, Frezza G, Mazza P, Pica A, Ammendolia I, Bendandi M, Neri S, Miniaci G
Institute of Hematology L. e A. Seràgnoli, University of Bologna, Italy.
Leuk Lymphoma. 1994 Apr;13(3-4):285-9. doi: 10.3109/10428199409056292.
Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survival and disease-free survival were 95% and 78%, respectively. In this study our goals were to reduce the irradiation volumes, to decrease the number of splenectomies performed at diagnosis, and to utilize radiotherapy alone in these patients. We were able to reduce the irradiation volumes in over 50% and 80% of the patients with disease in the upper torso and subdiaphragm, respectively. Furthermore, this therapeutic approach permitted us to reduce the acute and long-term toxic effects related to splenectomy and combined modality treatment.
1983年1月至1990年12月期间观察的99例“标准风险”IA-IIA期霍奇金淋巴瘤患者仅接受了放疗。完全缓解率为98%（97/99）。21例患者（21%）复发，其中17例（81%）获得了第二次完全缓解。预计9年总生存率和无病生存率分别为95%和78%。在本研究中，我们的目标是缩小照射体积，减少诊断时进行脾切除术的数量，并在这些患者中仅采用放疗。我们能够分别将上半身和膈下疾病患者的照射体积减少50%以上和80%以上。此外，这种治疗方法使我们能够减少与脾切除术和综合治疗相关的急性和长期毒性作用。
